Expertise in
7
conditions

Denis P. Franchimont

Brussels, BRU, BE 
Expertise in
7
conditions
Brussels, BRU, BE 

Overview

Denis Franchimont practices practicing medicine in Brussels, Belgium.

Mr. Franchimont is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Crohn's Disease, Viral Gastroenteritis, Alcoholic Cirrhosis, Colonoscopy, and Endoscopy.

He is actively involved in clinical research, co-authoring 73 peer reviewed articles and participating in 7 clinical trials.

Gender

Male

Locations

Brussels, BRU, Belgium
Other Locations
AZ Imelda
Bonheiden, VLG, Belgium
Route De Lennik 808, Anderlecht, BRU 1070, Belgium
AZ Groeninge
Kortrijk, VLG, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
Prospective, Non-Interventional, Observational Study in Patients With IBD Receiving IV or SC Vedolizumab Therapy to Observe Route of Administration Choices and Outcomes
Prospective, Non-Interventional, Observational Study in Patients With IBD Receiving IV or SC Vedolizumab Therapy to Observe Route of Administration Choices and Outcomes
Enrollment Status: Completed
Publish Date: August 06, 2024
Prospective Study to Assess the Efficacy of Switching to Infliximab in Moderately to Severely Active Chrohn's Disease Patients With Primary Non-response or Loss of Response to Adalimumab
Prospective Study to Assess the Efficacy of Switching to Infliximab in Moderately to Severely Active Chrohn's Disease Patients With Primary Non-response or Loss of Response to Adalimumab
Enrollment Status: Completed
Publish Date: January 05, 2023
Intervention Type: Drug
ENTYVIO® Real-World Outcomes in Bio-naïve Crohn's Disease Patients in Belgium, Australia, and Switzerland: An EVOLVE Observational Expansion Study
ENTYVIO® Real-World Outcomes in Bio-naïve Crohn's Disease Patients in Belgium, Australia, and Switzerland: An EVOLVE Observational Expansion Study
Enrollment Status: Completed
Publish Date: October 21, 2022
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 2
Multicentric, Double-blind, Placebo Controlled Clinical Trial With 5-hydroxytryptophan (5-HTP) in Patients With Inflammatory Bowel Disease in Clinical and Biologic Remission: Effect on Fatigue Scores
Multicentric, Double-blind, Placebo Controlled Clinical Trial With 5-hydroxytryptophan (5-HTP) in Patients With Inflammatory Bowel Disease in Clinical and Biologic Remission: Effect on Fatigue Scores
Enrollment Status: Completed
Publish Date: May 18, 2021
Intervention Type: Drug
Study Drug: 5-HTP
Study Phase: Phase 2
An Open Label Interventional Phase 4 Study to Evaluate Efficacy, Safety and Mucosal Healing of Early Versus Late Use of Vedolizumab in Ulcerative Colitis: the LOVE-UC Study (LOw Countries VEdolizumab in UC Study)
An Open Label Interventional Phase 4 Study to Evaluate Efficacy, Safety and Mucosal Healing of Early Versus Late Use of Vedolizumab in Ulcerative Colitis: the LOVE-UC Study (LOw Countries VEdolizumab in UC Study)
Enrollment Status: Completed
Publish Date: October 08, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 6 Less Clinical Trials

73 Total Publications

Exome sequencing directly implicates 68 genes in inflammatory bowel disease.
Exome sequencing directly implicates 68 genes in inflammatory bowel disease.
Journal: medRxiv : the preprint server for health sciences
Published: May 25, 2026

Frequently Asked Questions about Denis P. Franchimont

Is Denis P. Franchimont a top-rated expert for Crohn's Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Denis P. Franchimont is classified as an Distinguished expert for Crohn's Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Denis P. Franchimont participate in research or clinical trials?

Yes. Denis P. Franchimont has published 73 articles and abstracts on conditions like Crohn's Disease. You can view a list of Denis P. Franchimont's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Franchimont's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile